89Bio Inc reports results for the quarter ended December 31 - Earnings Summary
27/02/2025 23:17
89Bio Inc ETNB.OQ reported a quarterly adjusted loss of $1.02 per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of seven analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from $-1.03 to -53 cents per share. Reported revenue was zero; analysts expected zero. 89Bio Inc's reported EPS for the quarter was a loss of $1.02. The company reported a quarterly loss of $118.35 million. 89Bio Inc shares had risen by 17.8% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 2% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for 89Bio Inc is $33.00 This summary was machine generated from LSEG data February 27 at 11:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.77 | -1.02 | Missed |
| Sep. 30 2024 | -0.64 | -1.39 | Missed |
| Jun. 30 2024 | -0.57 | -0.48 | Beat |
| Mar. 31 2024 | -0.46 | -0.54 | Missed |